Search
Aboriginal children are at greater risk of rotavirus disease than non-Aboriginal children and delayed vaccine receipt is substantially higher
Substantial spatial clustering of notified tuberculosis was detected at region, zone and district level in Ethiopia
Admissions for ARI were higher in Western Australia and displayed greater socioeconomic disparities than England and Scotland, where ARI rates are increasing
Influenza vaccination recommendation by children’s hospital physicians and previous vaccine receipt in hospital was associated with vaccine uptake
Aboriginal children and children from lower socio-economic backgrounds were over-represented with OM-related hospitalizations but had fewer TTIs
One in four ED presentations in WA children are for ARIs, representing a significant out-of-hospital burden with some evidence of geographical disparity
This study addressed respiratory syncytial virus (RSV) infection during pregnancy
Gram-negative bacterial infections remain a major cause of morbidity and mortality in children and neonates globally, compounded by the rise of antimicrobial resistance. Barriers to paediatric antibiotic licencing lead to reduced availability of potentially effective agents for treatment. For children and neonates in the Oceania region, specific challenges remain including a paucity of surveillance data on local rates of antimicrobial resistance, and lack of availability of newer, more costly agents.
High nasopharyngeal pneumococcal carriage density is associated with severe pneumonia; however, little is known about factors that affect pneumococcal carriage density including pneumococcal vaccination. We describe pneumococcal density by clinical and demographic factors, and effect of 13-valent pneumococcal conjugate vaccine (PCV13) on density in Papua New Guinea (PNG), Lao People’s Democratic Republic (Lao PDR) and Mongolia, 3–6 years following national PCV13 introduction.
Between January 2022 and December 2023, there were 1,827 bloodstream infection (BSI) isolates in 1,745 children and adolescents reported to the Australian Group on Antimicrobial Resistance (AGAR) surveillance outcome programs, with 40% of episodes in children aged < 12 months.